ATP-sensitive potassium channel (K(ATP )channel) expression in the normal canine pancreas and in canine insulinomas by Donley, Vicky R et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Veterinary Research
Open Access Research article
ATP-sensitive potassium channel (KATP channel) expression in the 
normal canine pancreas and in canine insulinomas
Vicky R Donley, Erin K Hiskett, Aimee C Kidder and Thomas Schermerhorn*
Address: Kansas State University, Department of Clinical Sciences, 1800 Denison Ave, Manhattan, KS 66506-5606, USA
Email: Vicky R Donley - vdonley@vet.k-state.edu; Erin K Hiskett - ehiskett@vet.k-state.edu; Aimee C Kidder - akidder@vet.k-state.edu; 
Thomas Schermerhorn* - tscherme@vet.ksu.edu
* Corresponding author    
Abstract
Background: Pancreatic beta cells express ATP-sensitive potassium (KATP) channels that are
needed for normal insulin secretion and are targets for drugs that modulate insulin secretion. The
KATP channel is composed of two subunits: a sulfonylurea receptor (SUR 1) and an inward rectifying
potassium channel (Kir6.2). KATP channel activity is influenced by the metabolic state of the cell and
initiates the ionic events that precede insulin exocytosis. Although drugs that target the KATP
channel have the expected effects on insulin secretion in dogs, little is known about molecular
aspects of this potassium channel. To learn more about canine beta cell KATP channels, we studied
KATP channel expression by the normal canine pancreas and by insulin-secreting tumors of dogs.
Results: Pancreatic tissue from normal dogs and tumor tissue from three dogs with histologically-
confirmed insulinomas was examined for expression of KATP channel subunits (SUR1 and Kir6.2)
using RT-PCR. Normal canine pancreas expressed SUR1 and Kir6.2 subunits of the KATP channel.
The partial nucleotide sequences for SUR1 and Kir6.2 obtained from the normal pancreas showed
a high degree of homology to published sequences for other mammalian species. SUR1 and Kir6.2
expression was observed in each of the three canine insulinomas examined. Comparison of short
sequences from insulinomas with those obtained f r o m  n o r m a l  p a n c r e a s  d i d  n o t  r e v e a l  a n y
mutations in either SUR1 or Kir6.2 in any of the insulinomas.
Conclusion: Canine pancreatic KATP channels have the same subunit composition as those found
in the endocrine pancreases of humans, rats, and mice, suggesting that the canine channel is
regulated in a similar fashion as in other species. SUR1 and Kir6.2 expression was found in the three
insulinomas examined indicating that unregulated insulin secretion by these tumors does not result
from failure to express one or both KATP channel subunits.
Background
The ATP-sensitive potassium (KATP) channel is a crucial
component of the pancreatic beta cell insulin secretion
pathway and a target for drugs that modulate insulin
secretion. In the endocrine cells of the pancreas, KATP
channel is composed of two subunits: a sulfonylurea
receptor (SUR 1), which contains two adenine nucleotide
binding domains [1], and an inward rectifying potassium
channel (Kir6.2), which conducts potassium ions [2]. The
KATP channel is important for sensing the metabolic state
of the pancreatic beta cell and initiating the changes in
membrane potential that precede insulin exocytosis. In
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the presence of high concentrations of glucose, beta cell
metabolism of the sugar increases ATP production. The
resulting rise in the cellular ATP/ADP ratio causes closure
of KATP channels, which bind ATP and ADP at different
sites [3]. The decrease in potassium conductance caused
by channel closure depolarizes the cell membrane and
initiates a sequence of ionic events that ultimately trigger
insulin secretion [3].
Drugs that target pancreatic KATP channels are used to
modulate insulin secretion. Diazoxide and the sulfonylu-
rea class of drugs are the most important examples of
drugs that alter KATP channel activity as their principle
mechanism of action. These drugs have opposite actions
on KATP channel activity which is reflected by their effects
on insulin secretion. Diazoxide, a potent KATP channel
opener, inhibits insulin secretion, even in the presence of
glucose, by "locking" KATP channels in the open configura-
tion, which prevents cellular depolarization and prevents
the ionic events that normally precede insulin exocytosis
[4]. In contrast, the sulfonylurea drugs have the opposite
effect on KATP channel activity. These drugs cause KATP
channel closure, even in the absence of glucose, which
leads to membrane depolarization and enhanced insulin
secretion [5]. SUR 1 was discovered when research into
the mechanism of action of the sulfonylurea drugs indi-
cated that these drugs displayed high-affinity binding to a
protein that modulated insulin secretion [6]. Diazoxide
also binds to SUR 1, although at a different site than the
sulfonylureas, since diazoxide does not prevent sulfonylu-
rea binding [7,8]. Endogenous SUR1 ligands, such as
alpha-endosulfine, may also regulate insulin secretion [9].
Although sulfonylurea drugs and diazoxide have the
expected effects on insulin secretion from normal dogs
[10-13], little information is known about the canine beta
cell KATP channel that is the molecular target for these
drugs. Some but not all canine insulinomas respond to
diazoxide [14], suggesting the possibility that mutations
in the KATP channel could be responsible for drug failure
in some cases. Unregulated insulin secretion by the insuli-
noma could, in theory, result from any mutation of either
SUR 1 or Kir6.2 that promotes KATP channel closure or
impairs normal metabolic regulation. Unfortunately, lit-
tle has been reported about KATP channel mutations in
human insulin producing tumors and the authors are not
aware of any reports examining the KATP channel in canine
insulinoma. However, naturally occurring mutations of
SUR1 and Kir6.2 are known to cause a group of congenital
hyperinsulinemic disorders of humans collectively known
as persistent hypoglycemic hyperinsulinism of infancy
(PHHI) [15]. About 40 separate mutations in SUR1 and
three mutations in Kir6.2 have been described thus far
[15,16]. The development of methods to study the canine
KATP channel would permit more detailed study of canine
beta cell function and insulin secretion. Likewise, these
methods could also be used to learn more about canine
insulinoma, in particular the contribution of abnormal
KATP channel function to the unregulated insulin secretion
that characterizes these tumors.
The purpose of this study was to learn more about KATP
channel expression in normal canine pancreas and in
insulin-secreting endocrine tumors of the canine pan-
creas. The study goals were twofold: to develop RT-PCR
methods and reagents to study KATP channel expression in
the normal canine pancreas and to screen a series of
canine insulinomas to determine whether these tumors
have normal KATP channel expression.
Results
SUR 1 expression in normal canine pancreas
The results of RT-PCR for SUR1 expression in normal
canine pancreas are shown in Figure 1. The primers, which
were designed from the rat SUR1 nucleotide sequence,
amplified a 248 bp product from rat and dog pancreases.
Sequence analysis confirmed that the amplicon from rat
pancreas was rat SUR1, indicating that the primers specif-
ically amplified the desired product. The amplicon from
normal dog pancreas was also determined to be SUR1
based on shared base identity with SUR1 from other spe-
cies (Figure 2). The canine SUR1 sequence was verified by
repeat sequencing and placed in GenBank [Gen-
Bank:AY927669]. The partial sequence of canine SUR 1
was found to have a high degree of nucleotide identity
PCR primers designed against rat SUR1 amplified a single  band of expected size (248 bp) from rat (R) and dog (D) pan- creas Figure 1
PCR primers designed against rat SUR1 amplified a single 
band of expected size (248 bp) from rat (R) and dog (D) pan-
creas. Sequence analysis confirmed the identity of each band 
as SUR 1. The size markers (M) are shown on the left. The 
arrow indicates the approximate location of the 300 bp 
marker.BMC Veterinary Research 2005, 1:8 http://www.biomedcentral.com/1746-6148/1/8
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with corresponding SUR 1 sequences from humans
(93%), rat (93%), and hamster (92%).
Kir6.2 expression in normal canine pancreas
Expression of Kir6.2 was detected in normal canine pan-
creas using primers designed against rat Kir6.2  [Gen-
Bank:D50581]. These primers amplified a product of
expected size (approximately 167 bp) from rat and dog
pancreases. Sequence analysis revealed that the PCR prod-
uct from rat pancreas was 99% identical to the published
sequence for Kir6.2, indicating that RT-PCR yielded a spe-
cific product. However, these primers did not produce
clean, defined bands from canine pancreas (data not
shown). To further clarify canine Kir6.2 expression, a sec-
ond set of primers that were specific for canine Kir6.2 was
designed using sequence information contained in the
canine genome database [18]. These primers amplified a
well-defined DNA band of expected size (371 bp) from
normal canine pancreas (Figure 3). Sequence analysis
showed that the canine product had 100% identity with a
corresponding region of canine chromosome 21 [Gen-
Bank:AAEX01017445] contained in the canine genome
database [18]. The canine pancreatic Kir6.2 sequence was
verified by repeat sequencing and placed in GenBank
[GenBank:AY929390]. The partial sequence obtained for
canine Kir6.2 sequence shared extensive identity with Kir6.2
from other species (Figure 4). The canine Kir6.2 shares
95% identity with the predicted chimpanzee Kir6.2 but
also has substantial identities with Kir6.2 from human
(93%), mouse (90%), and rat (87%). The canine Kir6.2
was also compared to a predicted sequence for canine
Kir6.2  [GenBank:XM-542519] that is available in Gen-
Bank. The 271 bp Kir6.2sequence from normal canine pan-
creas has 100% identity with the predicted nucleotide
sequence of canine Kir6.2.
KATP channel subunit expression by canine insulinomas
Histologically-confirmed insulinomas from three dogs
were analyzed for SUR1 and Kir6.2 expression. For each
insulinoma, subunit expression was determined using the
previously described rat SUR 1 and canine Kir6.2 primers.
All three insulinomas were found to express the genes for
SUR 1 and Kir6.2 (Figure 5). The identities of the PCR
products obtained from each insulinoma were confirmed
by nucleotide sequencing. Analysis of SUR1 and Kir6.2
sequences obtained from insulinomas did not reveal any
mutations and were identical to the respective sequences
obtained from normal canine pancreas. The intensity of
SUR1 bands was noted to differ substantially among the
insulinomas (Figure 5, panel A). Semiquantitative analy-
sis comparing the OD of the SUR1 band with the OD of
GAPDH band (the reference gene) from each insulinoma
confirmed that SUR1 expression varied. Insulinoma #3
expressed SUR1 at a level that was 3.5-fold greater than
insulinoma #1 and 2-fold greater than insulinoma #2. In
contrast, expression levels of Kir6.2 were approximately
equal in all three insulinomas (data not shown).
Canine SUR1 shares a high degree of nucleotide identity with SUR1 from other mammalian species Figure 2
Canine SUR1 shares a high degree of nucleotide identity with SUR1 from other mammalian species. The alignment compares 
the partial sequence of canine SUR1 [GenBank:AY927669] with SUR1 from human [GenBank:AF087138], rat [Gen-
Bank:L40624], and hamster [GenBank:L40623]. Areas of sequence identity are shown in black and areas of non-identity are 
shown in white.BMC Veterinary Research 2005, 1:8 http://www.biomedcentral.com/1746-6148/1/8
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Discussion
The results demonstrate that the SUR 1 and Kir6.2 subunits
of the KATP channel are expressed in the pancreas of nor-
mal dogs. The combination of SUR1 and Kir6.2 comprises
the classical beta cell KATP channel and expression of this
subunit combination in the normal dog pancreas is con-
sistent with previous reports showing that this same com-
bination of subunits is expressed in the pancreatic beta
cells by other species [2,19] and by insulin-secreting beta
cell lines derived from the rat and mouse [2]. It is likely
that the SUR1 and Kir6.2 detected in whole pancreatic sam-
ples represent islet specific expression since KATP channel
subunit expression has not been reported in the exocrine
pancreas. SUR 1 and Kir6.2 expression is not specific to
beta cells, however, and are also expressed in islet alpha
cells, where they are involved in glucagon secretion
[20,21]. As the KATP channel subunits have similar func-
tion in all islet cells where they are expressed (e.g. sulfony-
lureas also stimulate glucagon secretion [21]) and since
beta cells are the predominant endocrine cell in the canine
islet, it may be concluded that the SUR1 and Kir6.2
detected in DNA isolated from whole pancreas reflects
beta cell expression in the dog, although it is likely that
other islet cells express the KATP channel also.
Because the subunit composition is the same, we predict
that the canine beta cell KATP channel is subject to the
same manner of metabolic regulation as the KATP channel
in other species, such as the rat, mouse, and human,
which have an identical KATP channel composition. The
mechanisms of sulfonyluea and diazoxide on the pancre-
atic beta cell have not been studied at the molecular level
in the dog but the results of this study predict that these
pharmacologic agents will act via the KATP channel to alter
insulin secretion. Indeed, in vivo studies have shown the
expected changes in serum insulin and glucose levels in
dogs treated with sulfonylureas or diazoxide [10-13].
The RT-PCR results also showed that all three insulinomas
examined expressed SUR 1 and Kir6.2. Thus, failure to
express one or both subunits cannot account for the
abnormal insulin secretion by these tumors. However,
variation in SUR1 expression was noted among the insuli-
nomas. In particular, expression in one tumor (insuli-
noma #3) was several fold greater than the other tumors.
It is not known whether the expression level of one or
both subunits plays a role in the abnormal insulin secre-
tion by canine insulinomas. The expression of the KATP
channel by insulinomas is consistent with the hypothe-
sized origin of these tumors from pancreatic beta cells or
other pancreatic endocrine tissue. The islet origin of
canine insulinomas is further supported by our findings
that these tumors also express glucokinase and insulin but
not amylase (V. Donley and T. Schermerhorn, unpub-
lished observations).
The current results do not eliminate the possibility that
the canine tumors express truncated versions of SUR1 or
Kir6.2, such as those described for some humans with
PHHI and unregulated insulin secretion [16,22,23]. Sim-
ple expression experiments do not provide information
about functional aspects of the KATP channel, however,
and our experiments would not have been able to detect
functional abnormalities of KATP channels that might be
present in the insulinomas. Many mutations do not affect
gene expression but instead affect one or more of the steps
beyond expression that are needed for proper channel
function. Among the reported subunit mutations associ-
ated with KATP channel dysfunction are mutations that
cause impaired translation into functional proteins
[16,22], abnormal protein trafficking [23], impaired pro-
tein folding [24], defective channel assembly [22,24], and
altered nucleotide sensitivity and substrate binding [16].
Many of the known KATP channel mutations leading to
unregulated insulin secretion are associated with human
PHHI. Most of these mutations affect SUR1 (there are over
40 reported human SUR1 mutations [15], while relatively
few are Kir6.2 mutations [16,22,23]. Many of the muta-
tions causing PHHI result in the production of KATP chan-
nels that lack activity. In the absence of KATP channel
activity to couple metabolic activity and membrane
potential, persistent calcium entry via voltage-sensitive
calcium channels promotes insulin secretion that contin-
ues despite profound hypoglycemia. It is possible that
mutations occurring in canine insulinomas might pro-
PCR primers designed against canine Kir6.2 amplified a single  band of expected size (371 bp) from dog pancreas (P) Figure 3
PCR primers designed against canine Kir6.2 amplified a single 
band of expected size (371 bp) from dog pancreas (P). 
Sequence analysis confirmed the identity of the band as Kir6.2. 
The size markers (M) are shown on the left. The arrow indi-
cates the approximate location of the 400 bp marker.BMC Veterinary Research 2005, 1:8 http://www.biomedcentral.com/1746-6148/1/8
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duce similar functional consequences. We screened
canine insulinomas for mutations in SUR1 and Kir6.2 by
comparing sequences obtained from insulinomas with
those obtained from normal dogs. Using direct sequence
comparison, no mutations were detected in the relatively
short SUR1 or Kir6.2 sequences obtained from the insuli-
nomas.
However, as the complete sequences of SUR1 and Kir6.2
from each insulinoma were not exhaustively screened for
mutations, it is not possible to determine with any cer-
tainty whether or not KATP  channel mutations were
responsible for the abnormal secretory function exhibited
by these tumors. The partial DNA sequence of canine
SUR1 obtained from these insulinomas is homologous to
a region that spans exons 7 and 8 of human SUR1 which
codes for the c-terminal end of the linker region between
the 7th and 8th transmembrane regions as well as a portion
of the 8th transmembrane domain of the SUR1 protein.
Several mutations in exon 8 have been found in humans
with PHHI [16], suggesting that this region should be
included when screening canine insulinomas for SUR1
Canine Kir6.2 shares a high degree of nucleotide identity with Kir6.2 from other mammalian species Figure 4
Canine Kir6.2 shares a high degree of nucleotide identity with Kir6.2 from other mammalian species. The alignment compares 
the partial sequence of canine Kir6.2 [GenBank:AY929390] with Kir6.2from chimpanzee [GenBank:XM521849], human [Gen-
Bank:BC040617], mouse [GenBank:NM-010602], and rat [GenBank:NM-031358] Areas of sequence identity are shown in 
black and areas of non-identity are shown in white.BMC Veterinary Research 2005, 1:8 http://www.biomedcentral.com/1746-6148/1/8
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mutations. However, the human SUR1 gene in humans is
large, containing 39 exons [16]. Mutations causing hyper-
insulinemia have been reported along the entire gene,
including introns [15,16]. Assuming the canine gene is
arranged similarly, mutation screening of SUR1 will not
be readily performed until the complete nucleotide
sequence of the normal canine gene is available. The same
holds true for Kir6.2, although this gene is considerably
smaller than SUR1 in the human and is likely to be similar
in the dog.
Conclusion
In conclusion, this study documents the expression of the
KATP channel subunits, SUR 1 and Kir6.2, in the normal
canine pancreas. The partial sequences of canine SUR1
and Kir6.2 obtained are highly similar to those from other
mammals, including humans, non-human primates, and
rodents. KATP channel subunit expression was detected in
all three canine insulinomas examined, indicating that
absence of subunit expression cannot account for the
abnormal insulin secretion observed with these tumors.
SUR 1 and Kir6.2  sequence comparisons with normal
canine pancreas did not reveal any mutations within the
sequences obtained from the canine insulinomas.
Methods
Animals
All normal pancreatic and insulinoma tissues were
obtained from dogs submitted necropsy examination or
from dogs that underwent surgery to remove an insuli-
noma. All pancreases used to determine KATP channel
expression in "normal" tissue was from dogs with no
known pathology or that had non-pancreatic pathology.
All dogs from which insulinoma tissue was obtained
exhibited clinical signs suggestive of insulinoma and had
a pancreatic mass at surgery. The diagnosis of insulinoma
was confirmed by histological examination in each case.
Rat pancreas served as control tissue for experiments
unless otherwise indicated. Rat pancreatic tissue was
obtained from normal Wistar rats that had been sacrificed
for reasons unrelated to this study. Samples were immedi-
ately snap frozen in liquid nitrogen and maintained at -80
C until used for RNA extraction.
PCR primers
Primers used in PCR reactions were designed against a rat
sequence for SUR 1 [GenBank:L40624] and a mouse
sequence for Kir6.2 [GenBank:D50581] [17]. A second set
of Kir6.2 primers was designed in our laboratory using
canine-specific sequence information recently made avail-
able through the canine genome project [18]. GAPDH
expression was used as an internal control for each exper-
iment. Primer pairs and their expected product size were
SUR1 (sense 5'-GGAGCAATCCAGACCAAG AT-3'; anti-
sense 5'-AGCCAGCAGAATGATGACAG-3', expected
product 248 bp), rat Kir6.2  (sense 5'-
TCCAACAGCCCGCTCTAC-3'; antisense 5'-GAT-
GGGGACAAAACGCTG-3', expected product 167 bp);
canine Kir6.2 (sense 5'-CCTACACCAGGTGGACATCC-3',
antisense 5'-CAGGCTGCGGTCCTCATCAA-3', expected
product 371 bp); GAPDH (sense 5'-ATCTTCCAG-
GAGCGAGAT-3'; antisense 5'-TGGTCATGAGTCCTTC-
CACGATA-3'; expected product 300 bp).
RNA isolation and reverse transcription-polymerase chain
reaction (RT-PCR) RT-PCR was performed to determine
the expression of SUR1 and Kir6.2 in canine pancreas and
in a series of three canine insulinomas. GAPDH gene
expression was used as an internal PCR control. To pre-
pare RNA, frozen tissue samples were homogenized using
a QIAshredder and RNA extracted in Trizol Reagent
according to manufacturer's instructions (Qiagen RNeasy
Panel A – PCR primers designed against rat SUR1 amplified a  single band of the expected size (248 bp) from each of the  three canine insulinomas examined (lanes labeled SUR1 1–3) Figure 5
Panel A – PCR primers designed against rat SUR1 amplified a 
single band of the expected size (248 bp) from each of the 
three canine insulinomas examined (lanes labeled SUR1 1–3). 
Sequence analysis confirmed the identity of each band as SUR 
1. GAPDH expression was used as a psoitive control (lanes 
labeled GAPDH 1–3). Semiquantitative analysis showed that 
SUR1 expression by insulinoma #3 was 3.5 and 2 fold greater 
than insulinomas #1 and #2, respectively (see text for expla-
nation). Size markers (M) are shown on the left. The arrows 
indicate the approximate location of the 300 bp marker. 
Panel B – PCR primers designed against canine Kir6.2 amplified 
a single band of expected size (371 bp) from normal pancreas 
(P) and from each of the three canine insulinomas (labeled 1–
3) examined. Sequence analysis confirmed the identity of 
each band as Kir6.2. Size markers (M) are shown on the left. 
The arrows indicate the approximate location of the 400 bp 
markerBMC Veterinary Research 2005, 1:8 http://www.biomedcentral.com/1746-6148/1/8
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Mini Kit). cDNA synthesis was carried out using a mixture
(19 µl) that included total RNA (5 µg), dNTP 10 mmol/L,
random hexamers 100 ng/µl, RNasin 20 IU and reverse
transcriptase (Superscript II RT, Invitrogen) 25 IU. The
mixture was incubated for 50 min at 42 C according to
manufacturer's instructions, after which the reaction was
terminated by heating the reaction to 70 C for 15 min.
PCR amplification was carried out in 25 µL reactions that
contained: 0.5 µL template cDNA, 1 µL of each specific
oligonucleotide primer, 0.1 µL Invitrogen Platinum Taq
DNA Polymerase, 2.5 µL 10× buffer, 0.75 µl MgCl2, 1 µL
dNTPs and 18.95 µL distilled water. PCR cycles for ampli-
fication of SUR1 and Kir6.2 were as follows. SUR1: 94 C for
5 min; followed by 35 cycles of 94 C for 0.5 min, 59 C for
0.5 min, 72 C for 1.5 min and then 72 C for 30 min.
Kir6.2: 94 C for 5 min; followed by 35 cycles of 94 C for
0.5 min, 58.6 C for 0.5 min, 72 C for 1.5 min; then 72 C
for 30 min. Products from the PCR reaction were resolved
by electrophoresis on a 1.2% agarose gel and detected
with ethidium bromide staining and UV light. The iden-
tity of the PCR products was confirmed by sequence anal-
ysis performed using an automated ABI 3700 DNA
Analyzer (Kansas State University, Department of Plant
Pathology).
Semiquantitative analysis of KATP subunit expression in 
insulinomas
Optical densities (OD) of PCR bands were determined
from gel images using ImageJ software (Rasband, W.S.,
ImageJ, U. S. National Institutes of Health, Bethesda, Mar-
yland, USA, http://rsb.info.nih.gov/ij/, 1997–2005). Sem-
iquantitative analysis was performed by comparing the
OD of the SUR1 and Kir6.2 bands to the OD of a reference
gene (GAPDH) from the same insulinoma. The ratio of
SUR1 (or Kir6.2) to GAPDH provides a semiquantitative
basis for comparison of expression levels between differ-
ent tumors.
List of abbreviations
KATP – ATP-sensitive potassium channel
Kir6.2 – inward rectifying potassium channel 6.2
PHHI – persistent hypoglycemic hyperinsulinism of
infancy
OD – optical density
SUR 1 – sulfonylurea receptor 1
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